PACB
PACB
US69404D1081
Pacific Biosciences of Californ
Loading chart...

Company Profile

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Latest News

Related stocks

CBLL
CBLL • United States
CeriBell, Inc.
23.63 USD
906.87M USD 1Y +89.1%
BBNX
BBNX • United States
Beta Bionics, Inc.
17.63 USD
951.07M USD 1Y -21.2%
LMRI
LMRI • United States
Lumexa Imaging Holdings, Inc.
10.54 USD
1.01B USD
ALMR
ALMR • United States
Alamar Biosciences, Inc.
25.27 USD
1.75B USD
TNDM
TNDM • United States
Tandem Diabetes Care, Inc.
16.11 USD
1.12B USD 1Y +2.2%
AHCO
AHCO • United States
AdaptHealth Corp.
6.06 USD
824.49M USD 1Y -32.3%
BFLY
BFLY • United States
Butterfly Network, Inc.
8.25 USD
2.2B USD 1Y +199.6%
ENOV
ENOV • United States
Enovis Corporation
17.69 USD
1.02B USD 1Y -45.2%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
96.7% p.a.
Max Drawdown (5Y)
-97.0%
Sharpe Ratio (5Y)
-0.42
Beta Factor
2.19
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
High market risk: Beta of 2.19 indicates above-average volatility compared to the broader market.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Elevated Short-Term Volatility: 3Y volatility (101.7%) is noticeably higher than the 5Y average (96.7%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (96.7% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -98.2% in the extended horizon.
ende